Does CARMENA mark the end of cytoreductive nephrectomy for metastatic renal cell carcinoma?

[1]  R. Motzer,et al.  JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Russo,et al.  Cytoreductive Nephrectomy - Patient Selection Is Key. , 2018, The New England journal of medicine.

[3]  K. Bensalah,et al.  Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[4]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[5]  C. Porta,et al.  Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). , 2018 .

[6]  L. Collette,et al.  Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) , 2017 .

[7]  R. Motzer,et al.  Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[8]  G. Oades,et al.  Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. , 2016, JAMA oncology.

[9]  Steven L. Chang,et al.  Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Tamboli,et al.  Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. , 2016, European urology.

[11]  J. Hainsworth,et al.  Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. , 2016, The Lancet. Oncology.

[12]  T. Choueiri,et al.  Non-clear cell renal cell carcinoma, part 2: therapy. , 2015, Clinical advances in hematology & oncology : H&O.

[13]  T. Choueiri,et al.  Non-clear cell renal cell carcinoma, part 1: histology. , 2015, Clinical advances in hematology & oncology : H&O.

[14]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[15]  A. Kibel,et al.  Cytoreductive nephrectomy in patients with metastatic non‐clear‐cell renal cell carcinoma (RCC) , 2014, BJU international.

[16]  J. Suh,et al.  Histologic Variations and Immunohistochemical Features of Metastatic Clear Cell Renal Cell Carcinoma , 2013, Korean journal of pathology.

[17]  V. Margulis,et al.  Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. , 2013, European urology.

[18]  S. Boorjian,et al.  Survival after complete surgical resection of multiple metastases from renal cell carcinoma , 2011, Cancer.

[19]  D. Berney,et al.  The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  V. Margulis,et al.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? , 2010, Cancer.

[21]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[23]  R. Flanigan.  Debulking Nephrectomy in Metastatic Renal Cancer , 2004, Clinical Cancer Research.

[24]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[25]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[26]  R. Portenoy,et al.  Management of cancer pain , 1999, The Lancet.

[27]  A. Renshaw,et al.  Subtypes of renal cell carcinoma. Different onset and sites of metastatic disease. , 1999, American journal of clinical pathology.

[28]  P. Choyke,et al.  Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. , 1997, The Journal of urology.

[29]  J. Blay,et al.  Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma , 1997, International journal of cancer.

[30]  C. Cleeland,et al.  Pain and its treatment in outpatients with metastatic cancer. , 1994, The New England journal of medicine.

[31]  J. J. Barney.  A twelve-year cure following nephrectomy for adenocarcinoma and lobectomy for solitary metastasis. , 1944, Transactions of the American Association of Genito-Urinary Surgeons.

[32]  G. Palapattu,et al.  Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. , 2002, Reviews in urology.